Discover Inovio Pharmaceuticals' Q1 2025 earnings call insights, including progress on INO-3107's BLA submission, reduced expenses, and groundbreaking ...

Sirius Therapeutics Inc. raised nearly $50 million in a series B2 financing round May 9 to support its pipeline of small interfering RNA (siRNA) molecules for cardiovascular disease indications.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Inc.; Ultragenyx Pharmaceutical Inc.; Freeline Therapeutics Holdings plc; LogicBio Therapeutics, Inc.; and MeiraGTx Holdings plc. In January 2024, Charles River Laboratories launched off-the-shelf Rep ...